

Final Plenary Session

Frank de Vries PharmD PhD

Maastricht UMC+, Utrecht University, the Netherlands

EAHP Prague 13 Sept 2014



Disclosures

- From 2006-2010, Frank de Vries has worked as a senior epidemiologist for the UK Medicines and Healthcare Products Regulatory Agency. He has been involved in commissioned research for various pharmaceutical companies.
- Some of the research presented in this workshop on 12-13
 September 2014 has been conducted as part of the IMI PROTECT study, which is a public private partnership between
 various stakeholders including academia, the European
 Medicines Agency and various pharmaceutical companies.



Objectives

- Robertial Impact of Benjadiarenine Use on the Rate of Rin Fractures in Five Large Entropean Countries and the Linited to understand study methods and took research
- to apply ir

DOI 10.1007/800223.012.9003.8 ORIGINAL RESEARCH

these many of the to real the service of the servic

T.P. Khang. F. de Vries. J.S. B. Galdenhere. O. H. Klungel. N. J. Robinson. Luisa Inárez.



States


Objectives

- to understand study hierarchy, databases, methods and tools of pharmacoepidemiology research
- to apply individually break out sessions on these methods and tools
- to perform literature research, meta-analysis, and combine it with drug utilization data to estimate population attributable risks (PARs)



Method - Estimation of pooled RR

PAR = Population Attributable Risk





Slides from groups



Objectives

- Estimate PARs of a certain outcome performing
 - a) a meta-analysis and
 - b) collect national drug utilization data



Learning goals

- 1. Application of pharmacoepi
- 2. Overview of EU pharmacoepi datasources
- 3. Case-control vs cohort design
- 4. Pro's & con's pharmacoepi study designs
- 5. Calculate risk ratios, odds ratios risk difference
- Recognize desing, exposure & outcome in papers



Learning goals

- 7. Critical appraise papers with exposure & outcome
- 8. Assess mislcassification of risk estimation
- 9. Classfiy bias (confounding, information, selection)
- 10. List solutions for each type of bias
- 11. Apply revman
- 12. Steps & bias of systematic review
- 13. Identify online EU DU resources



Learning goals

- 14. Estimate DDD/1000 inhabitants
- 15. To combine pooled risk estimates with DU data
- 16. Transform DU data into prevalence of use
- 17. Estimate population impact of a drug
- 18. To test for limitations.



Feedback to home

+ Khong paper with 7 easy steps.....



Thank you so much!













frank.de.vries@mumc.nl

